To determine whether the donor EBV isolate is transmitted to the recipient via the aUograft and causes PTLD, EBV isolates from four cases of PTLD in cadaveric heart and/or lung transplant recipients were compared with the donor isolates by PCR and DNA sequence analysis. Two recipients who were EBV seronegative at transplantation acquired an EBV isolate indistinguishable from that of the donor and developed PTLD. In contrast, in two patients who were seropositive before transplantation, the donor isolate differed from that present in PTLD of the recipient. The results suggest that the acquisition of donor EBV is a risk factor for PTLD development in a previously seronegative transplant recipient.
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Post-transplant lymphoproliferative disease (PTLD) is one of the commonest causes of morbidity and mortality in immunosuppressed solid organ transplant recipients after the immediate post-operative period. PTLD occurs in 1-10% of transplanted individuals, is highest in incidence in the first post-transplant year and is more common in children than adults (Ho et al., 1988) . Clinically, PTLD may vary from infectious mononucleosis-like illnesses to solid localized tumours and is fatal in about 70 % of cases (reviewed by Thomas et al., 1995) .
High cumulative dose of immunosuppressive therapy required for the maintainance of the allograft is a risk factor for the development of PTLD, with those receiving heart and/or lung transplants, retransplants or experiencing recurrent episodes of rejection being particularly at risk. The ubiquitous human herpesvirus Epstein-Barr virus (EBV) is aetiologically associated with PTLD; viral DNA and virus-coded antigens are almost invariably detected in the tumour cells. Around 50% of PTLD cases develop after primary EBV infection, and since children are more likely to be seronegative than adults prior to transplant, this prob-* Author for correspondence. Fax +44 171 637 4314. e-mail d.crawford@lshtm.ac.uk ably accounts for the increased incidence of PTLD in children (reviewed by Thomas et al., 1995) .
In order to define intervention strategies for PTLD it is important to determine the source of infecting virus. Since most seroconversions leading to PTLD occur shortly after transplant, the donor organ and/or transfused blood are likely routes of virus transmission. To investigate this, we have exploited the fact that there are numerous short repeat DNA sequences in the EBV genome and the numbers of repeats of a given DNA sequence vary between the viruses isolated from different individuals. Thus, PCR amplification of these repeat regions gives rise to products of unique sizes for individual virus isolates (Falk et al., 1995) . In order to compare donor-recipient virus isolates, we decided to amplify the 39 bp DNA repeat region within the coding exon of the EBV nuclear antigen (EBNA)-6 gene, which in the prototype virus B95-8 is repeated three times (Baer et al., 1984) .
Four transplant recipients with EBV-associated PTLD were studied. All patients were transplanted with cadaveric heart and/or lungs at the Cardiothoracic Unit, Harefield Hospital, Middlesex, UK. All received a cyclosporin/azathioprine immunosuppression regimen following the transplantation. In addition, acyclovir (ACV) (200 mg five times a day) was given for the first 3 months after transplant. Two patients (T2 and T4) 0001-3786 © 1996 SGM (40) * Patient T2 was transplanted with double lungs which were rejected and a second double lung transplant was performed 1 month after the first. PTLD developed 3 months after the first and 2 months after the second transplant.
t Patient T4 died from chronic graft failure.
received anti-thymocyte globulin for the treatment of graft rejection. EBV serological status was determined in all transplant recipients and organ donors by testing sera for IgG antibodies to EBV viral capsid antigen by the standard method of indirect immunoflourescence (Henle & Henle, 1966) . Tumour biopsy material was stained for EBNA complex using polyclonal human serum and for EBV encoded small RNAs (EBERs) by routine methods (Brooks & Thomas, 1995) .
DNA was extracted from donor spleen lymphocytes, PTLD material and, where possible, recipient peripheral blood mononuclear cells (PBMC) by routine methods (Sambrook et al., 1989) . To obtain PCR template, 5 ml of mouth wash was concentrated by centrifugation at 24000 g for 2 h at 4 °C (Sixbey et al., 1989) , the pellet resuspended in 50 gl of sterile distilled water and treated with 100 gg/ml of Proteinase K (Promega) for 1 h at 37 °C. Samples were boiled for 10 rain before use in PCR. DNA (1 gg) and 20gl of mouth wash were amplified in a 50 gl reaction volume. Each reaction contained 10 mM-Tris-HC1 (pH 8.3), 50 mM-KC1, 1 mMMgC12, 0"01% gelatin, 200 gM of each dATP, dTTP, dGTP, dCTP, 0"1 I~M of each primer and 1 unit of Taq polymerase (Promega). The amplification programme consisted of 3 min initial denaturation at 94 °C, and 30 cycles of denaturation at 94 °C for 30 s, annealing at 55 °C for 60 s and extension at 72 °C for 90 s, with a final incubation at 72 °C for 10 min. A 2.5 gl volume of the PCR product from the first run was reamplified in a 50 gl reaction volume by another 30 cycles, using the inner or nested primers (nested PCR; annealing temperature 65 °C). The primers used were specific for a 39 bp repeat DNA sequence in the EBNA-6 gene of EBV genome (outer primer pair, 5' ACA CTT GAG TTC CAT GTC GC Y and 5' TGT AAT CAC TGG CAA AGG GC 3"; inner or nested primer pair, 5' TAT CGC ACG AAG AAC AAC CCC 3' and 5' AGA TGT GGG AAC TGG GAG ACC 3'). A 10 gl volume of nested PCR product was run on a 1-5 % agarose gel and Southern hybridized with 32P-labelled EBNA-6-specific plasmid probe. The presence of amplifiable DNA in samples was determined by control PCR using human fl-globin primers described elsewhere (Saiki et al., 1985) .
PCR products were directly sequenced by automated DNA sequencing methods (commercially performed by the Department of Molecular Medicine, King's College School of Medicine and Dentistry, London, UK).
The clinical data on transplant recipients with PTLD are presented in Table 1 . PTLD developed between 2.5 and 6 months post-transplant and was diagnosed by routine histology on the biopsy material. All tumours gave positive staining for EBNA complex and for EBERs. Patients T1 and T3 were seropositive for EBVspecific antibodies prior to transplant whereas patients T2 and T4 were EBV seronegative and seroconverted after transplant (Table 1) .
Human fl-globin PCR showed the presence of amplifiable DNA in all samples (data not shown). PTLD material from patients T1 and T3 (EBV seropositive at transplant) gave PCR products which differed in size from their respective donors indicating that, in both cases, the donor EBV isolate was not present in the tumour tissue and therefore was not responsible for PTLD development (Fig. 1 a) . In patient T3 the same isolate was detected in peripheral blood and PTLD tissue suggesting that this was the dominant virus isolate in this individual. In contrast, amplification of the EBNA-6 DNA sequence from the PTLD tissue from patients T2 and T4 (seronegative at transplant) gave bands which were indistinguishable in size from that of their respective donors (Fig. l a, b) . In the case of patient T2, who received a lung transplant on two occasions from two separate donors, the EBV DNA band from the PTLD was identical in size to that of the second donor and differed from that of the first (Fig. 1 a) . Additional studies o n p a t i e n t T4 showed a n identical sized D N A b a n d f r o m p e r i p h e r a l b l o o d at the time of P T L D d e v e l o p m e n t , at 1 a n d 2 years p o s t -t r a n s p l a n t a n d f r o m m o u t h w a s h 7 m o n t h s after t r a n s p l a n t (Fig. 1 b) . In order to c o n f i r m the identity o f the P C R p r o d u c t s of patients T2 a n d T4 a n d their respective d o n o r s , direct D N A s e q u e n c i n g was carried out. P a t i e n t T2 a n d the d o n o r were s h o w n to have P C R p r o d u c t s of identical 730 bp D N A sequence with the 39 b p s e q u e n c e repeated 11 times in b o t h cases. Similarly, b o t h p a t i e n t T4 a n d the d o n o r h a d identical 535 bp P C R p r o d u c t s with six repeats. This d a t a strongly suggest the t r a n s m i s s i o n o f the d o n o r E B V isolate following t r a n s p l a n t a t i o n to the previously seronegative recipients. l 172
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Herpesviruses as a group are well known to reactivate in the immunocompromised host. Transmission of donor EBV to the recipient has been shown in bone marrow transplant recipients and in one case of kidney transplant recipient (Gratama et al., 1988; Van Gelder et al., 1994) . In addition, an earlier case report describes the transmission of EBV from a single donor to two recipients in heart/lungs and kidney with resultant PTLD containing the donor virus in both cases (Cen et al., 1991) . We have now demonstrated that donor-derived EBV can be transmitted in heart and/or lungs to the organ recipient and give rise to severe or fatal EBV-driven lymphoproliferation.
The exact mechanism by which the donor virus is transmitted via the transplanted organs to the recipient is not known, although it is known that in solid organ transplant recipients, the virus-infected cells in PTLD are of recipient origin (Cen et al., 1991) . Thus, the donor virus may either be transmitted in a cell-free state or be released from the donor cells in the recipient. It is possible that a sufficient number of EBV-carrying B cells remain in blood within the allograft and pass into the circulation of the recipient; the virus would then enter the lytic cycle and infect the recipient B cell population. Alternatively, heart and lung tissue might contain foci of EBV-carrying cells which, in the absence of any preexisting EBV-specific immune control in seronegative transplant recipients, acts as a site of virus replication. In this regard, all four patients studied received ACV for 3 months. This drug inhibits EBV replication (Colby et al., 1980) and might be expected to prevent reactivation in vivo. However, both our seronegative patients (T2 and T4) seroconverted and developed PTLD while on ACV. Thus, prescribing low dose ACV does not inhibit EBV transmission. Additionally, the fact that patient T4 produced the donor EBV isolate in mouth wash 7 months after seroconversion demonstrates that EBV introduced parenterally can relocate to the pharynx, presumably in a B lymphocyte. However, the cell type which supports virus replication in the pharyngeal epithelium has not been identified.
In our study, both seronegative patients acquired EBV isolates indistinguishable from that of the donor following the transplant and this resulted in the development of EBV-associated PTLD, thus suggesting that the acquisition of donor EBV isolate is an important risk factor for PTLD development in previously seronegative transplant recipients. This route of infection could be prevented by matching donor and recipient for EBV status; however, this is not a practical proposition at present. Alternatively, PTLD could perhaps be prevented by the use of an EBV vaccine or by covering the patient with passively transfused autologous EBV-specific cytotoxic T cells during times of intense immunosuppression (Rooney et al., 1995) .
